TypeZero Technologies, LLC, a Charlottesville-based healthcare technology company, raised an undisclosed amount of funding.
The round was led by CIT GAP Funds with participation from other investors.
Led by Chad Rogers, CEO, TypeZero Technologies is developing the inControl Diabetes Intelligence Platform, which is a patented software solution designed to integrate a universe of medical devices, services, and applications, transforming raw data into control solutions.
Its proprietary intelligent control system aims to improve the safety, outcomes and quality of life for patients with Type 1 and Type 2 diabetes. The platform integrates data from approved medical devices in an intelligent, interoperable network for effective blood glucose management to allow patients to manage their blood glucose from hour-to-hour.
In addition to its artificial pancreas software platform, TypeZero is developing a suite of cloud based applications and analytical services, which utilize its core algorithms to provide risk analysis, prediction, clinician advice, patient support and training for patients, caregivers, clinicians and insurers.